Fog Pharmaceuticals

Edit info

Founded: 2015

Location: Cambridge, MA

Employee range: 50 - 200

Clinical stage: Clin1/Clin2

Therapy area: Oncology

Drug types: ONC

Lead product: FOG-001

Funding: $178M D Nov 2022; $107M C Mar 2021; $66M May 2018

Investors: ARCH Venture Partners, Milky Way Investments, Fidelity Management & Research Company, VenBio Partners, Deerfield Management, GV, Cormorant Asset Management, Invus, Farallon Capital Management, HBM Healthcare Investments, Casdin Capital, PagsGroup

fogpharma.com

linkedin.com

job board

Drug notes:

5 undisclosed programs RD multiple cancers

About:

FogPharma is developing treatments for currently undruggable disease targets. Many drugs can be classified as monoclonal antibodies that cannot access the cell interior or as small molecules that lack specificity for interior targets. FogPharma is focusing on a new class of drugs - Helicon polypeptides - that combine the targeting power of monoclonal antibodies with the cell-penetrating ability of small molecules. The polypeptides designed by FogPharma have an alpha helical shape, which confers unique drug-like properties and greater stability. FogPharma evaluates thousands of new peptides weekly in biochemical and cell-based assays to select hits to develop. FogPharma’s lead product, FOG-001, targets β-catenin, which is commonly overactive in cancer.